No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 66.2x · 10Y median 19.9x · 90th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:59:20.339Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T19:59:20.339Z. Latest historical point 2021-11-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T19:59:20.339Z. Latest historical point 2021-11-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T19:59:20.339Z. Latest historical point 2021-11-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T19:59:20.339Z. Latest historical point 2021-11-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Tango Therapeutics, Inc. (TNGX) stock was $21.88 as of Oct 6, 2026, 3:55 PM EDT, down 5.22% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +195.9% · 3-year avg +24.3%/yr · 5-year avg +10.6%/yr
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments.
Biotechnology · Boston, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.34
Revenue Est.
$3.28M
Last Quarter Results
EPS
$-0.37
vs Estimate
$-0.32
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TNGX | $3.56B | $21.88 | -5.22% | +195.88% | +10.60% | N/A | N/A |
| 2VCYT | $3.55B | $44.43 | -6.80% | +32.24% | +1.45% | +19.91% | vs TNGX |
| 3IRTC | $3.53B | $107.55 | -1.41% | -37.74% | +12.95% | N/A | vs TNGX |
| 4XENE | $3.53B | $36.54 | -2.73% | -5.13% | +4.61% | +17.07% | vs TNGX |
| 5IDYA | $3.48B | $36.55 | -3.97% | +37.49% | +7.32% | N/A | vs TNGX |
| 6CELC | $3.47B | $71.18 | -3.31% | +45.49% | +34.40% | N/A | vs TNGX |
forward FY estimate
N/A
$0.00
vs Estimate
$1.56M
Consensus Rating
Based on 11 analysts
Average Price Target
$45.18
+106.5% upside
Low
$24.00
Current
$21.88
High
$69.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.43 | $-0.35 | $-0.31 | 9 |
| Quarter ending Dec 2026 | $-0.46 | $-0.38 | $-0.33 | 9 |
| Quarter ending Mar 2027 | $-0.38 | $-0.38 | $-0.38 | 6 |
| Quarter ending Jun 2027 | $-0.40 | $-0.40 | $-0.40 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.56 | $-1.42 | $-1.31 | 10 |
| FY 2027 | $-2.18 | $-1.70 | $-1.55 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $3.28M | $3.28M | $3.28M | 7 |
| Quarter ending Dec 2026 | $636727.00 | $636727.00 | $636727.00 | 10 |
| Quarter ending Mar 2027 | $1.32M | $1.32M | $1.32M | 5 |
| Quarter ending Jun 2027 | $1.32M | $1.32M | $1.32M | 5 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $6.06M | $6.06M | $6.06M | 7 |
| FY 2027 | $3.44M | $3.44M | $3.44M | 7 |
